Results 11 to 20 of about 289,170 (184)

Definition of Parameters and Thresholds to Detect MYCN Amplification in Retinoblastomas [PDF]

Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin
Retinoblastoma is a malignant childhood neoplasm where MYCN amplification defines a subset of tumors with worse prognosis. FISH (fluorescence in situ hybridization) represents a fast and reliable method to measure gene copy numbers in various tumors but has not yet been systematically evaluated in retinoblastoma.
H-U Schildhaus
exaly   +5 more sources

MYCN amplification drives an aggressive form of spinal ependymoma. [PDF]

Acta Neuropathol, 2019
Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prognosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central nervous ...
Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW, Scheie D, Kruse A, Harter PN, Kastelan M, Wagner M, Hartmann C, Benzel J, Maass KK, Khasraw M, Sträter R, Thomas C, Paulus W, Kratz CP, Witt H, Kawauchi D, Herold-Mende C, Sahm F, Brandner S, Kool M, Jones DTW, von Deimling A, Pfister SM, Reuss DE, Pajtler KW.   +29 more
europepmc   +10 more sources

Regulation of MYCN expression in human neuroblastoma cells [PDF]

BMC Cancer, 2009
Background Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB.
de Vries I, Hulsbergen-van de Kaa Christina A, van Leeuwen Frank N, van Bokhoven Hans, Jacobs Joannes FM, Adema Gosse J, Hoogerbrugge Peter M, de Brouwer Arjan PM   +7 more
doaj   +3 more sources

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma

Cancers, 2023
Cancer is a disease caused by (epi)genomic and gene expression abnormalities and characterized by metabolic phenotypes that are substantially different from the normal phenotypes of the tissues of origin.
Champezou, Lydia, Koutsi, Marianna A., Agelopoulos, Marios, Giannopoulou, Angeliki-Ioanna, Pouliou, Marialena, Vatsellas, Giannis, Piperi, Christina   +6 more
core   +6 more sources

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines

Molecular Medicine Reports, 2019
Neuroblastoma derived from primitive sympathetic neural precursors is a common type of solid tumor in infants. MYCN proto-oncogene bHLH transcription factor (MYCN) amplification and 1p36 deletion are important factors associated with the poor prognosis ...
Aygun, Nevim, Altungöz, Oğuz
core   +5 more sources

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. [PDF]

Nature Genetics, 2018
Amplification of the locus encoding the oncogenic transcription factor MYCN is a defining feature of high-risk neuroblastoma. Here we present the first dynamic chromatin and transcriptional landscape of MYCN perturbation in neuroblastoma.
Karlin, KL, Hirsch, RA, Jacobson, Z, Scott, TG, Nabet, B, Chesler, L, Fulciniti, M, Erb, MA, Lin, CY, Zeid, R, Lawlor, MA, Poon, E, Lopez, MA, Winter, GE, Bradner, JE, Munshi, NP, Reyes, JM, Westbrook, TF, Polaski, DR   +18 more
core   +5 more sources

CD133 expression and amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma

Journal of International Medical Research, 2018
Objectives Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN is amplified in nearly half of patients with NB, and its association with rapid disease progression and poor outcome is controversial.
Zhi-Yong Zhong, Bao-Jun Shi, Hui Zhou, Wen-Bo Wang   +3 more
doaj   +2 more sources

Pheno-MYCN maps the morphological footprint of MYCN amplification in paediatric neuroblastoma

MYCN amplification has long been a prognostic marker in paediatric neuroblastoma, yet is typically assayed in bulk, alongside rather than within the heterogeneous tissue architecture pathologists assess.
Olga Fourkioti, Louis Chesler, Binghao Chai, Chris Bakal, Reed Naidoo, John Ciaran Hutchinson, Matt De Vries, Sally George   +7 more
core   +2 more sources

Downregulation of MYCN through PI3K inhibition in mouse models of pediatric neural cancer [PDF]

Frontiers in Oncology, 2015
The MYCN proto-oncogene is associated with poor outcome across a broad range of pediatric tumors. While amplification of MYCN drives subsets of high risk neuroblastoma and medulloblastoma, dysregulation of MYCN in medulloblastoma (in the absence of ...
Tene Aneka Cage, Yvan eChanthery, Yvan eChanthery, Louis eChesler, Matthew eGrimmer, Matthew eGrimmer, Zachary eKnight, Kevan eShokat, William A Weiss, William A Weiss, William A Weiss, William A Weiss, W. Clay Gustafson, W. Clay Gustafson   +13 more
doaj   +2 more sources

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells

EBioMedicine, 2015
Dysregulated expression of MYC family genes is a hallmark of many malignancies. Unfortunately, these proteins are not amenable to blockade by small molecules or protein-based therapeutic agents.
Long Gu, Peiguo Chu, Robert Lingeman, Heather McDaniel, Steven Kechichian, Robert J. Hickey, Zheng Liu, Yate-Ching Yuan, John A. Sandoval, Gregg B. Fields, Linda H. Malkas   +10 more
doaj   +2 more sources